Effects of the combined administration of risedronate and menatetrenone on bone loss induced by tacrolimus in rats
{{output}}
Tacrolimus, a calcineurin inhibitor, affects bone metabolism and increases the risk of fracture due to marked bone loss. Bisphosphonates increase the bone mineral density (BMD) in osteoporosis patients. Menatetrenone has less positive effects on BMD but reduce... ...
